FGFR4 (V550M)

FGFR4 · Variant type: point · HGVS: p.V550M

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Brigatinib	95.5%	4.5%	82.96
2	Futibatinib	94.8%	5.2%	98.48
3	Upadacitinib	70.7%	29.3%	97.98
4	Erdafitinib	59.6%	40.4%	95.71
5	Pralsetinib	55.8%	44.2%	93.43
6	Ponatinib	54.9%	45.1%	78.23
7	Fedratinib	51.8%	48.2%	96.21
8	Defactinib	45.5%	54.5%	92.68
9	Sunitinib	39.0%	61.0%	91.73
10	Ceritinib	37.8%	62.2%	95.44
11	Pemigatinib	34.8%	65.2%	98.23
12	Baricitinib	33.5%	66.5%	97.99
13	Pacritinib	32.3%	67.7%	88.64
14	Alpelisib	27.8%	72.2%	97.22
15	Repotrectinib	26.1%	73.9%	84.21
16	Alectinib	25.1%	74.9%	95.49
17	Infigratinib	23.2%	76.8%	98.24
18	Entrectinib	23.1%	76.9%	93.69
19	Fostamatinib	22.9%	77.1%	96.74
20	Selpercatinib	20.1%	79.9%	96.72
21	Osimertinib	11.9%	88.1%	97.24
22	Pazopanib	11.9%	88.1%	97.49
23	Avapritinib	11.3%	88.7%	97.73
24	Umbralisib	9.6%	90.4%	98.74
25	Lorlatinib	9.5%	90.5%	97.24

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Brigatinib	95.5%	73.3%	+22.2%
Futibatinib	94.8%	97.9%	-3.1%
Upadacitinib	70.7%	—	—
Erdafitinib	59.6%	98.0%	-38.5%
Pralsetinib	55.8%	64.6%	-8.8%
Ponatinib	54.9%	96.7%	-41.8%
Fedratinib	51.8%	—	—
Defactinib	45.5%	—	—
Sunitinib	39.0%	—	—
Ceritinib	37.8%	48.2%	-10.4%
Pemigatinib	34.8%	93.9%	-59.2%
Baricitinib	33.5%	—	—
Pacritinib	32.3%	—	—
Alpelisib	27.8%	96.8%	-69.0%
Repotrectinib	26.1%	—	—
Alectinib	25.1%	36.3%	-11.2%
Infigratinib	23.2%	94.7%	-71.5%
Entrectinib	23.1%	—	—
Fostamatinib	22.9%	—	—
Selpercatinib	20.1%	49.1%	-29.0%
Osimertinib	11.9%	—	—
Pazopanib	11.9%	43.1%	-31.2%
Avapritinib	11.3%	—	—
Umbralisib	9.6%	—	—
Lorlatinib	9.5%	—	—

Cancer	Organ	Source
carcinoma_breast	Breast	ref
carcinoma_large_intestine	Large Intestine	ref
rhabdomyosarcoma_soft_tissue	Soft Tissue	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.3ms